|
1
|
MAS
|
406 (+3SD) Hyperplasia 565 (+4SD)
|
Octreotide LAR 30 mg (monthly- 18 months)
|
+ Cabergoline 1 mg/week
|
Pegvisomant 20 mg/day
| |
C
|
333 (-1SD) NA
|
7
|
|
2
|
MENI
|
Invasive Macroadenoma (36 × 27 × 28 mm) 1259 (+4SD)
|
Trans-sphenoidal surgery
|
Octreotide LAR 30 mg monthly (6 months - growth of adenoma with visual disturbance; 3 surgeries)
|
+ Cabergoline with visual (1 mg/week)
|
Proton therapy
|
NC
|
689 (+2.5SD) 14 × 10 mm (-68%)
|
3
|
|
3
|
AIP
|
Invasive Macroadenoma (21 × 26 mm) 997 (+4SD)
|
Lanreotide LAR 90 mg monthly (6 months)
|
Octreotide LAR 30 mg monthly + cabergoline (1 mg/week)
|
Transphenoidal surgery
| |
NC
|
1184 (+4SD) 10 × 12 × 9 mm (-50%)
|
4
|
|
4
|
AIP
|
Invasive Macroadenoma (16 × 21 × 11 mm) 934 (+4SD)
|
Lanreotide LAR 60 mg monthly (6 months)
|
Transphenoidal surgery
| | |
C
|
451 (0SD) No visible adenoma
|
6
|
|
5
|
Negative genetic analysis (Carney, MEN1, AIP)
|
Non invasive macroadenoma (19 × 14 × 20 mm)
|
Lanreotide LAR 60 mg monthly
| | | |
C
|
282 (+1SD) No visible adenoma
|
4
|
|
6
|
Negative genetic analysis (MEN1, AIP)
|
777 (+3SD) Invasive macroadenoma (26 × 26 × 32 mm)
|
Octreotide LAR 30 mg monthly (6 months) added to the previous Dopamine agonist treatment (Cabergoline 1,5 mg/week)
| | | |
NC
|
717(+3SD) 34 × 21 × 23 mm (+6%)
|
2
|
|
7
|
Negative genetic analysis (Carney, MEN1, AIP)
|
574 (+4SD) Microadenoma (7,6 × 9 × 7,5 mm)
|
Trans-sphenoidal surgery
| | | |
C
|
504 (+1,5 SD) No visible adenoma
|
4
|
